QHL-339

QHL-339 is a preclinical small molecule drug conjugate (SMDC) being developed by Affinity Biopharmaceutical for the treatment of solid tumors. It is designed as a precision-guided chemotherapy that utilizes a targeting moiety to deliver a platinum-based cytotoxic payload directly to tumor cells. This approach aims to enhance the therapeutic index of platinum-based agents by increasing local concentration at the tumor site while minimizing systemic toxicity associated with conventional chemotherapy. As an SMDC, it leverages a small molecule ligand for targeting rather than a large antibody, potentially allowing for better tissue penetration in dense solid tumors.